Our Compound TLD-1433 Granted Second US Patent for Novel Anti-Cancer Drugs

More exciting news about our licensed PDT agent as it is granted a second patent due to the success of the first clinical trial for non-muscle invasive bladder cancer.

Read more …

Our work featured by NSRIT!

Our work has been featured by the Nova Scotia Research and Innovation Trust.

Read more …

CBC radio reports on our recent NSERC RTI award!

McFarland Labs to use new equipment to capture the inner workings of drugs in cells in fight against cancer.

Read more …

Our licensed PDT agent nears human clinical trials!

Many things have happened with our licenced PDT agent over the past few months. Continue on to learn of the advances our drug is making.

Read more …

Milestone reached in pre-clinical development!

Our licensed compound TLD-1433 has been identified as the lead photodynamic compound for human clinical trials!

Read more …

Theralase CEO describes our licensed photosensitizers for cancer therapy on CBC TV!

President and CEO of Theralase, Roger Dumoulin-White, discusses the Company's progress on  its ground breaking anti-cancer research on CBC’s The Lang and O’Leary Exchange.

Read more …

Our photosensitizers for Theralase anti-cancer photodynamic therapy nears human trials!

The latest research on Photo Dynamic Compound (PDC) technology from Theralase Technologies, proven effective in the destruction of bacteria and cancer, was peer reviewed and invited to be published in Coordination Chemistry Reviews as the company prepares for human clinical trials.

Read more …

Theralase Anti-Cancer Technology Validated in Prestigious US Chemistry Publication

Theralase Technologies Inc. announced today that its latest research on Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, was peer reviewed and invited to be published in the prestigious US Elsevier publication, Coordination Chemistry Reviews.

Read more …

Theralase Advances Anti-Cancer Technology Platform

Theralase Technologies Inc. announced today that it has advanced its anti-cancer technology platform through an executed research agreement with Acadia University. 

Read more …

Thriving in Unlikely Places

A press release outlining some of the events happening in the McFarland Labs and the importance of working in a lab as a student, from the perspectives of Jordan Gibson, and Marc Hetu.

Read more …